| Literature DB >> 30186616 |
Simone Niederhäuser1, Luzia Klauser1, Jürg Bolliger1, Ute Friedel2, Sarah Schmitt2, Maja Ruetten3, Craig E Greene4, Giovanni Ghielmetti2.
Abstract
CASEEntities:
Keywords: Mycobacterium nebraskense; Switzerland; cutaneous mycobacteriosis; non-tuberculous mycobacteria; susceptibility testing
Year: 2018 PMID: 30186616 PMCID: PMC6113737 DOI: 10.1177/2055116918792685
Source DB: PubMed Journal: JFMS Open Rep ISSN: 2055-1169
Figure 1(a) Nodular skin lesions surrounding the base of the right ear and spreading along the right side of the face. (b) The first debulking procedure addressed the dorsal nodules on the medial side of the pinna. (c) During the second procedure the skin lesions on the side of the face were removed and the defect was closed with a myocutaneous advancement flap. (d) The wounds in the head region healed with almost no scar formation and no nodular lesions reappeared 6 months after treatment
Figure 2(a) Nodular skin lesions at the tail base. (b) The lesion extending to the spinous processes was excised completely and closed with a single pedicle advancement flap. (c) Healing of the surgical incisions was uneventful. Normal growth of hair was observed and no nodular lesions reappeared 6 months after treatment
Figure 3(a) The granulomatous infiltration consisting of numerous epithelioid macrophages, lymphocytes, several plasma cells and scarce neutrophils (haematoxylin and eosin stain; scale bar 50 μm). (b) Histological image of the affected skin showing myriad rod-shaped red stained intra- and extra-cytoplasmic acid-fast bacteria (Ziehl–Neelsen stain; scale bar 50 μm)
Antimicrobial susceptibility testing performed on the original Mycobacterium nebraskense isolate using a broth microdilution method for slowly growing non-tuberculous mycobacteria
| Antimicrobial | Range (µg/ml) | MIC indicating resistance* | MIC values measured | Interpretation* |
|---|---|---|---|---|
| Clarithromycin | 0.06–64 | >16 | ⩽0.06 | S |
| Rifabutin | 0.25–8 | >2 | ⩽0.25 | S |
| Ethambutol | 0.5–16 | >4 | 4 | S |
| Isoniazid | 0.25–8 | – | 2 | – |
| Moxifloxacin | 0.12–8 | >2 | ⩽0.12 | S |
| Rifampin | 0.12–8 | >1 | ⩽0.12 | S |
| Trimethoprim–sulfamethoxazole | 0.12–2.38/8–152 | >2/38 | 0.25/4.75 | S |
| Amikacin | 1–64 | >32 | ⩽1 | S |
| Linezolid | 1–64 | >16 | ⩽1 | S |
| Ciprofloxacin | 0.12–16 | >2 | ⩽0.12 | S |
| Streptomycin | 0.5–64 | – | ⩽0.5 | – |
| Doxycycline | 0.12–16 | – | 1 | – |
| Ethionamide | 0.3–20 | – | 2.5 | – |
Minimal inhibitory concentration (MIC) values indicating resistance to testing for Mycobacterium kansasii, according to Clinical and Laboratory Standards Institute M24-A2, 2011
S = Susceptible